| 摘要 |
<p>The present invention is related to a method for predicting a clinical response of a patient suffering from or at risk of developing a neoplastic disease to a given mode of treatment by determination the status of at least one hormone receptor selected from the group comprising estrogen receptor, progesterone receptor and/or androgen receptor, said method comprising the steps of:
a) obtaining a biological sample from said patient;
b) determining the status of at least one hormone receptor selected from the group comprising estrogen receptor, progesterone receptor and/or androgen receptor in said sample, using at least two determinations selected from the group comprising:
aa) determining the expression level of the RNA transcripts of at least one gene encoding for a hormone receptor selected from the group comprising estrogen receptor, progesterone receptor and/or androgen receptor, and/or
bb) determining the DNA amplification level of at least one gene encoding for a hormone receptor selected from the group comprising estrogen receptor, progesterone receptor and/or androgen receptor, and/or
cc) determining the presence or absence of at least one single nucleotide polymorphism of at least one gene encoding for a hormone receptor selected from the group comprising estrogen receptor, progesterone receptor and/or androgen receptor;
c) comparing the pattern of expression level(s) of aa), amplification level(s) of bb) and/or the single nucleotide polymorphism(s) of cc) determined in step b) with one or several reference pattern(s) of expression and/or amplification levels and/or single nucleotide polymorphisms; and
d) predicting therapeutic outcome for said given mode of treatment in said patient from the outcome of the comparison in step c).</p> |
